Connect Biopharma/$CNTB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Connect Biopharma
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
Ticker
$CNTB
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
62
ISIN
US2075231017
Website
CNTB Metrics
BasicAdvanced
$56M
-
-$0.31
-0.29
-
Price and volume
Market cap
$56M
Beta
-0.29
52-week high
$1.12
52-week low
$0.51
Average daily volume
90K
Financial strength
Current ratio
10.246
Quick ratio
9.827
Long term debt to equity
0.717
Total debt to equity
1.134
Profitability
EBITDA (TTM)
-20.597
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-66.10%
Operating margin (TTM)
-81.69%
Effective tax rate (TTM)
-1.46%
Revenue per employee (TTM)
$420,000
Management effectiveness
Return on equity (TTM)
-18.66%
Valuation
Price to revenue (TTM)
2.123
Price to book
0.67
Price to tangible book (TTM)
0.67
Price to free cash flow (TTM)
-1.635
Free cash flow yield (TTM)
-61.16%
Free cash flow per share (TTM)
-61.17%
Growth
Earnings per share change (TTM)
-69.19%
3-year earnings per share growth (CAGR)
-50.93%
CNTB News
AllArticlesVideos
Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress
GlobeNewsWire·1 week ago
Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress
GlobeNewsWire·3 weeks ago
Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Connect Biopharma stock?
Connect Biopharma (CNTB) has a market cap of $56M as of June 21, 2025.
What is the P/E ratio for Connect Biopharma stock?
The price to earnings (P/E) ratio for Connect Biopharma (CNTB) stock is 0 as of June 21, 2025.
Does Connect Biopharma stock pay dividends?
No, Connect Biopharma (CNTB) stock does not pay dividends to its shareholders as of June 21, 2025.
When is the next Connect Biopharma dividend payment date?
Connect Biopharma (CNTB) stock does not pay dividends to its shareholders.
What is the beta indicator for Connect Biopharma?
Connect Biopharma (CNTB) has a beta rating of -0.29. This means that it has an inverse relation to market volatility.